About CQDM
Structure and Governance
Board of Directors
The Board of Directors is made up of representatives from the industry, the academic milieu and the government. The Board has the power to create committees that are deemed relevant with regard to governance, strategy, financing and account auditing, among others.
Chairman
Léon Gosselin
Co-founder of Axcan Pharma
Directors
Bruno-Marie Béchard Marinier
Professor, Université de Sherbrooke
Michel Chrétien
Professor, University of Ottawa
Michael Cordingley
Senior Vice-President, Research and Development, Boehringer Ingelheim Canada
Jean Davignon
Professor, Université de Montréal
Richard Fajzel
General Manager, Oncolgy Business Unit, Pfizer Canada Inc.
Max Fehlmann
President and Chief Executive Officer
Neil Maresky
Vice-President, Medical Affairs, AstraZeneca Canada Inc.
Donald Olds
President and CEO, Presagia Corporation
Vassilios Papadopoulos
Director, Research Institute of the McGill University Health Center (MUHC)
Ken Pastor
General Partner, CTI Capital
Secretary
François Painchaud
Lawyer, Partner, ROBIC, LLP
Honorary Members
Paul Lévesque
President and CEO, Pfizer Canada
Marion McCourt
President and CEO, AstraZeneca Canada Inc.
Observers
Stéphanie Michaud
Deputy Director, Business-Led Networks of Centres of Excellence (BL-NCE)
Michèle Houpert
Manager of Health and Biotechnology, Ministère du Développement Économique, de l’Innovation et de l’Exportation (MDEIE)